Tetyana V. Svyatenko

Prof. Tetyana V. Svyatenko

Dnipro State Medical University
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
DLDanielle Levine
Danielle Levine
ZEZeev Even-Chen
Zeev Even-Chen
ILIrina Lipets
Irina Lipets
OPOlga A. Pritulo
Olga A. Pritulo
Tetyana V. SvyatenkoTetyana V. Svyatenko
Tetyana V. Svyatenko
AGAlice Gottlieb
Alice Gottlieb

7 May 2021 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
TLThomas Luger
Thomas Luger
UAUladzimir Adaskevich
Uladzimir Adaskevich
MAMaryna Anfilova
Maryna Anfilova
XDXia Dou
Xia Dou
NMNikolay N. Murashkin
Nikolay N. Murashkin
ZZZuotao Zhao
Zuotao Zhao
Atopic dermatitis is a chronic relapsing, inflammatory skin disorder associated with skin barrier dysfunction, the prevalence of which has increased dramatically in developing countries. In this article, we propose a treatment algorithm for patients with mild‐to‐moderate and severe atopic dermatitis flares in daily clinical practice. An international panel of 15 dermatology and allergy experts from eight countries was formed to develop a practical algorithm for the treatment of patients with atopic dermatitis, with a particular focus on topical therapies. In cases of mild‐to‐moderate atopic dermatitis involving sensitive skin areas, the topical calcineurin inhibitor pimecrolimus should be applied twice daily at the first signs of atopic dermatitis. For other body locations, patients should apply a topical calcineurin inhibitor, either pimecrolimus or tacrolimus, twice daily at the first signs of atopic dermatitis, such as pruritus, or twice weekly in previously affected skin areas. Emollients should be used regularly. Patients experiencing acute atopic dermatitis flares in sensitive skin areas should apply a topical corticosteroid twice daily or alternate once‐daily topical corticosteroid/topical calcineurin inhibitor until symptoms improve. Following improvement, topical corticosteroid therapy should be discontinued and patients switched to a topical calcineurin inhibitor. Maintenance therapy should include the use of pimecrolimus once daily for sensitive areas and tacrolimus for other body locations. This treatment algorithm can help guide clinical decision‐making in the treatment of atopic dermatitis.

20 September 2023 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
PCPavel Chernyshov
Pavel Chernyshov
SMServando Eugenio Marrón Moya
Servando Eugenio Marrón Moya
Dimitra KoumakiDimitra Koumaki
Dimitra Koumaki
NPNives Pustišek
Nives Pustišek
LMLiana Manolache
Liana Manolache
Lucia Tomas-AragonesLucia Tomas-Aragones
Lucia Tomas-Aragones
Background The Infants and Toddlers Dermatology Quality of Life (InToDermQoL) is the dermatology-specific proxy health-related quality of life (HRQoL) instrument for children from birth to 4 years. The aim of the present study was to confirm the responsiveness and establish minimal clinically important difference (MCID) for the InToDermQoL. Methods Parents of children with skin diseases were asked to fill in the InToDermQoL at the initial visit (T1) and subsequent consultation (T2). We hypothesized that correlations between change scores of the InToDermQoL and change scores of global assessment of clinical severity by dermatologists and by patients’ parents should be above 0.3. The receiver operating characteristic (ROC) curves method was also used for confirmation of responsiveness and determination of MCIDs of the InToDermQoL. The area under the ROC curve (AUC) was used as an indicator of responsiveness. Results Results of 442 patients were included. Correlations between change scores of age-specific versions of the InToDermQoL and change scores of global assessment of clinical severity by dermatologists and by patients’ parents were above 0.3 (0.46-0.74). AUCs for age-specific versions of the InToDermQoL were acceptable (above 0.7) or excellent (above 0.8). Estimated MCIDs for the InToDermQoL were as follows: 3 points of total score change for 0–11 months, 5 for 1–2 years and 3 or 4 for 3–4 years version. Estimated MCIDs for the InToDermQoL version for 1–2-year-old children was higher than MCIDs for the 3–4-year-old version despite the higher number of items in the latter. Therefore a MCID of 5 was recommended for both these versions. Conclusions Responsiveness for all age-specific versions of the InToDermQoL questionnaire was confirmed. MCIDs for the InToDermQoL are proposed as follows: 3-point change of the total score for age version 0–11 months and 5-point for the age versions 1–2 years and 3–4 years.

2 December 2022 in Apuntes Universitarios
Verified
Journal Article
Open access
IBIryna Borysiuk
Iryna Borysiuk
RYRoksolana Yaremkevych
Roksolana Yaremkevych
Tetyana V. SvyatenkoTetyana V. Svyatenko
Tetyana V. Svyatenko
VSVasyl Striukov
Vasyl Striukov
Oleksandr P. KrupskyiOleksandr P. Krupskyi
Oleksandr P. Krupskyi
Resumen El estudio tuvo como objetivo evaluar la efectividad del aprendizaje a distancia para estudiantes de medicina ucranianos durante la pandemia de COVID-19. Se identifican problemas universales y específicos de las especialidades médicas de la educación a distancia. La investigación estuvo dirigida específicamente a rastrear la dinámica de mejora de las condiciones para implementar el proceso educativo durante el período de adaptación de las medidas de cuarentena. El estudio involucró análisis de contenido, entrevistas grabadas en audio por computadora (CARI), entrevistas personales, entrevistas en profundidad y análisis cualitativo y cuantitativo de los resultados de la investigación empírica. Se presenta el modelo de diagnóstico en dos etapas del estado de la educación a distancia en las facultades de medicina profesional de Ucrania (2020-2021). Los resultados del experimento lineal mostraron una tendencia positiva en: la calidad de Internet y la disposición del lugar de trabajo de los estudiantes de medicina, capacitación especial en tecnologías de educación a distancia, el uso de plataformas educativas unificadas, reducción del nivel de estrés en los estudiantes y aumento de la objetividad de la evaluación. Los estereotipos sobre la educación a distancia como forzada e ineficaz en el desarrollo de habilidades prácticas (se mantuvieron estables). Las tecnologías en línea en la educación médica requieren un apoyo científico y metodológico calificado para la enseñanza.

28 November 2023 in Actual problems of modern medicine
Verified
Journal Article
Open access
PDF file
ISInessa Serbina
Inessa Serbina
KКKuzma Кhobzei
Kuzma Кhobzei
TLTetyana Lіadova
Tetyana Lіadova
OLOleksandr Litus
Oleksandr Litus
SVSvitlana Vozianova
Svitlana Vozianova
YOYuliya Ovcharenko
Yuliya Ovcharenko
Alopecia areata is an immune-mediated disease resulting from the interaction of genetic factors and exogenous triggers, leading to the activation of the Janus Kinases - Signal Transducer and Activator of Transcription signaling pathway, the formation of non-specific autoimmune inflammation and disruption of immune tolerance of hair follicles. Alopecia areata has an unpredictable course with a non-scarring type of hair loss, it can affect the hair part of the head and/or hair in other areas, it can be manifested by damage to the nail plates. The psychotraumatic impact of this disease can be compared to the consequences of life-threatening or disabling diseases. For this reason, the degree of negative impact of alopecia areata on the quality of life may not correlate with the objective condition of patients, which is often not taken into account in the diagnosis and treatment of the disease. Despite the variety of treatment options available, achieving effective and safe disease control is not always straightforward. Treating patients with alopecia areata and comorbid conditions can be particularly challenging and may require close collaboration between specialists from various fields. For these and other reasons, there is significant dissatisfaction among patients regarding alopecia areata and its treatment. The systematic organization, unification, and adaptation of modern knowledge about alopecia areata have led to the creation of two algorithms: a diagnostic algorithm and a therapeutic algorithm. These algorithms provide a differentiated approach to patient management, with age, disease severity, clinical form, disease activity stage, comorbid pathology, prognostic factors, and patient quality of life taken into account. Agents with immunosuppressive action belong to the main group of drugs in the treatment of alopecia areata, according to the antigenic concept of the pathogenesis of the disease. Ongoing work is being done to update treatment protocols to include JAK inhibitors and other preparations, taking into based on new developments and the expanding pharmaceutical market.

1 June 2015
Verified
Journal Article
Closed access
Tetyana V. SvyatenkoTetyana V. Svyatenko
Tetyana V. Svyatenko
OSO Starostina
O Starostina